Tianyi Medical (301097.SZ) subsidiary obtained drug registration certificates for several new products

Zhitong Finance App News, Tianyi Healthcare (301097.SZ) issued an announcement. The company's subsidiary Ningbo Tianyi Pharmaceutical Technology Co., Ltd. (“Tianyi Pharmaceutical”) recently received several “Drug Registration Certificates” issued by the State Drug Administration.

The low-calcium peritoneal dialysis solution and peritoneal dialysate approved this time were all declared using the “one drug, multiple specifications” method, and were continuously approved. The related product is a peritoneal dialysis treatment liquid used to treat patients with end-stage kidney disease. Metabolic waste from the body is removed through peritoneal dialysis, and water-electrolyte and acid-base balance disorders are corrected. Its core component, glucose, is used as an penetrating agent, and can provide three glucose concentration specifications of 1.5%, 2.5%, and 4.25% to meet the ultrafiltration needs of different patients; electrolytes and buffer bases such as sodium chloride, calcium chloride, magnesium chloride, and sodium lactate help maintain the balance of electrolytes and acid-base in the patient's body.

Related products use lactate as a buffer system. Among them, the low-calcium formula can reduce the risk of hypercalcemia, etc., is more suitable for the clinical needs of long-term dialysis patients, and can be directly used for peritoneal dialysis treatment without additional configuration, which helps simplify clinical operation and improve treatment safety.